This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

KEW Group Inc. Announces Completion Of Private Financing Round

CAMBRIDGE, Mass., Feb. 24, 2014 /PRNewswire/ -- KEW Group Inc. (KEW), a privately held oncology services company located in Cambridge, Mass., announced today the recent closing of a private round of financing with Cardinal Health (NYSE: CAH) and The Bolyston Street Group. KEW is focused on providing state-of-the-art diagnostic services to help inform and advance community oncologists' treatment decisions for their patients.

"We believe there is a strong need to arm community oncologists with rapidly advancing genomics-based tumor diagnostic tools that, until now, have largely been available only at large cancer treatment and academic centers," commented M. Kathleen Behrens Wilsey,  KEW CEO. "We are very pleased with this financing milestone, as it provides us with critical capital to continue to build and expand the reach of our offerings to community oncologists across the country."

John P. Sullivan, VP Strategy and Corporate Development, Cardinal Health, will represent the company's investment on KEW's Board of Directors. Additionally, KEW and Cardinal Health will continue to develop a strategic relationship to mutually benefit KEW's oncology testing services and Cardinal Health Specialty Solutions' relationship with community oncologists. The Boylston Street Group, a group of private investors in the Boston area, will be represented on KEW's Board of Directors by Valerie Jo Friedman. Leerink Partners, LLC served as the exclusive placement agent for the financing.

"Cardinal Health Specialty Solutions is pleased to partner with KEW for the provision of molecular diagnostics services to the patients and practices we serve," said Meg Fitzgerald, President of Cardinal Health Specialty Solutions. "KEW not only has developed leading-edge tumor genetic testing; they share our vision of supporting community oncology practices and innovating to improve cancer care for patients everywhere. By investing in the company, we further ensure the strength and alignment of our partnership and our combined ability to continue to develop information and service offerings that make a difference today and for the future."

KEW also cited recent changes to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a potential catalyst for encouraging uptake among clinicians of services such as those offered by KEW. One relevant update involves a recommendation for clinicians to use multiplex, next-generation sequencing analysis for lung cancer patients; another identifies the importance of testing KRAS and NRAS genes for colorectal cancer patients.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,064.28 -57.73 -0.34%
S&P 500 1,995.22 -4.90 -0.24%
NASDAQ 4,557.7470 -11.8740 -0.26%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs